3-way replicate vs. 4-way [GxP / QC / QA]

posted by drmuneesh – 2009-08-17 07:46 (6151 d 11:32 ago) – Posting: # 4049
Views: 10,803

Dear HS

Thank you for the reply. We are planning 4-period replicate design to reduce the number of subjects also. Highly variable drug like risedronate having intrasubject variability of 50-80% would require too many subjects in case of 3-period design. 3-period design may be ok for drugs having intrasubject variability of 30-50%.

Please suggest if I am wrong.

Regards

Dr Muneesh Garg

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
167 visitors (0 registered, 167 guests [including 36 identified bots]).
Forum time: 19:18 CEST (Europe/Vienna)

I have finally come to the konklusion
that a good reliable set ov bowels
iz worth more to a man
than enny quantity of brains.    Josh Billings

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5